Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs.
The company develops P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC).
It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers.
In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma.
Further, it is developing P-PSMA-101, an allogeneic CAR-T product candidate for treating mCRPC.
Additionally, the company engages in the development of P-OTC-101, a liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; and P-PAH-101, a liver-directed gene therapy for the in vivo treatment of phenylketonuria.
Poseida Therapeutics, Inc. has a research collaboration and license agreement with Takeda Pharmaceuticals USA, Inc., F.
Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 14, 24 | -0.25 Increased by +44.44% | -0.42 Increased by +40.48% |
| Mar 26, 24 | -0.27 Increased by +30.77% | -0.39 Increased by +30.77% |
| Nov 9, 23 | -0.35 Decreased by -138.04% | -0.29 Decreased by -20.69% |
| Aug 8, 23 | -0.32 Increased by +53.62% | -0.53 Increased by +39.62% |
| May 9, 23 | -0.45 Increased by +51.61% | -0.45 |
| Mar 9, 23 | -0.39 Decreased by -2.05 K% | -0.22 Decreased by -77.27% |
| Nov 10, 22 | 0.92 Increased by +235.29% | -0.65 Increased by +241.54% |
| Aug 11, 22 | -0.69 Increased by +6.76% | -0.76 Increased by +9.21% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 9.35 M Decreased by -91.96% | -31.78 M Decreased by -145.13% | Decreased by -339.80% Decreased by -661.30% |
| Jun 30, 23 | 20.01 M Increased by +641.22% | -27.46 M Increased by +38.34% | Decreased by -137.19% Increased by +91.68% |
| Mar 31, 23 | 10.34 M Increased by +620.77% | -40.21 M Increased by +32.03% | Decreased by -388.73% Increased by +90.57% |
| Dec 31, 22 | 9.92 M Increased by +31.66 K% | -33.32 M Decreased by -2.27 M% | Decreased by -335.85% Decreased by -7.24 K% |
| Sep 30, 22 | 116.31 M Increased by +N/A% | 70.41 M Increased by +265.97% | Increased by +60.54% Decreased by N/A% |
| Jun 30, 22 | 2.70 M Increased by +N/A% | -44.53 M Increased by +2.58% | Decreased by -1.65 K% Decreased by N/A% |
| Mar 31, 22 | 1.44 M Increased by +N/A% | -59.15 M Decreased by -54.39% | Decreased by -4.12 K% Decreased by N/A% |
| Dec 31, 21 | 31.24 K Increased by +N/A% | 1.47 K Increased by +104.06% | Increased by +4.70% Decreased by N/A% |